Therapeutic protein selection in simulated in vivo conditions
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDorothy Kim, Michael Marlow
Life of this patent
Estimating the term…
Abstract
A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.
Claims10
A method of determining an effect of non-specific interactions on monoclonal antibody-antigen interactions in simulated blood conditions, comprising:
- (a) contacting a solution comprising a blood protein and a monoclonal antibody with a biosensor, wherein a surface of the biosensor comprises an antigen that specifically binds to the monoclonal antibody, and wherein said blood protein does not specifically bind to said monoclonal antibody;
- (b) allowing the monoclonal antibody to bind to the antigen;
- (c) determining an amount of the monoclonal antibody bound to the antigen using biolayer interferometry;
- and
- (d) comparing the amount of the monoclonal antibody bound to the antigen to a control threshold to determine an effect of non-specific interactions,
- wherein the control threshold is a normalized response to an ideal, dilute, or semi-dilute solution.
Dependencies are inferred from the claim text.